DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
| Autor: | Katarzyna Grzela, Alicja Krejner-Bienias, Tomasz Grzela |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Dipeptidyl Peptidase 4 Immunology Review Disease Type 2 diabetes DPP4 medicine.disease_cause Antiviral Agents Diabetes mellitus medicine Humans Immunology and Allergy Intensive care medicine Dipeptidyl peptidase-4 Coronavirus Dipeptidyl-Peptidase IV Inhibitors SARS-CoV-2 business.industry Public health Diabetes COVID-19 General Medicine medicine.disease COVID-19 Drug Treatment Holy Grail Diabetes Mellitus Type 2 Gliptins business |
| Zdroj: | Archivum Immunologiae et Therapiae Experimentalis |
| ISSN: | 1661-4917 0004-069X |
| Popis: | A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink